Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of TLC-2716
NCT05483998Phase 1Completed
- Sponsor
- OrsoBio
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of TLC-2716 in hypertriglyceridemia and Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by OrsoBio. Primary endpoints: Number of subjects with treatment-emergent adverse events in single ascending dose, Number of subjects with clinically significant change from Baseline in vital signs in SAD and 6 more. Started Sep 2022; status: completed.
02
Drugs
TLC-2716
03
Conditions
hypertriglyceridemiaNonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05483998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05483998.